featured
Safety and Effectiveness of Self-Administered Intranasal Etripamil for Atrioventricular Nodal–Dependent Supraventricular Tachycardia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial
Lancet 2023 Jun 15;[EPub Ahead of Print], BS Stambler, AJ Camm, M Alings, P Dorian, H Heidbuchel, J Houtgraaf, PR Kowey, JL Merino, B Mondésert, JP Piccini, SD Pokorney, PT Sager, A Verma, JM Wharton, DB Bharucha, F Plat, S Shardonofsky, M Chen, JE IpFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.